Cryoport, Inc.

Insider Trading Arrangements and Policies

On June 3, 2025, Jerrell Shelton, our Chief Executive Officer and Chairman of the Board of Directors, entered into a trading plan, which is not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Shelton’s plan covers the potential sale of up to 356,064 shares of our common stock to be acquired upon the exercise of stock options that are expiring in August 2025. Transactions under Mr. Shelton’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of a cooling-off period. Mr. Shelton’s plan will terminate on the earlier of August 11, 2025 or the date all shares subject to the plan have been sold.

On June 10, 2025, Dr. Ramkumar Mandalam, amember of our Board of Directors, entered into a trading plan, which is not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Dr. Mandalam’s plan covers the potential sale of up to 80,000

shares of our common stock to be acquired upon the exercise of stock options that are expiring in August 2025. Transactions under Dr. Mandalam’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of a cooling-off period. Dr. Mandalam’s plan will terminate on the earlier of August 14, 2025 or the date all shares subject to the plan have been sold.

No other director or officer (as defined in Exchange Act Rule 16a-1(f)) adopted or terminated a “Rule 10b5–1 trading arrangement” or a “non-Rule 10b5–1 trading arrangement,” each as defined in Item 408 of Regulation S-K of the Securities Act of 1933, as amended, during thethree months ended June 30, 2025.